Garrett Motion 株価情報 (NASDAQ: GTX)

最新ニュース Garrett Motion (NASDAQ:GTX) 株価情報

GARRETT MOTION INC

Garrett Motion

Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.

Garrett Motion Inc

Global Trading Xenocurrency - United States Dollar

Piper Sandler analyst James Fish maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Neutral and raises the price target from $60 to $64.

News

Price Target

Analyst Ratings

CSCO

Piper Sandler Maintains Neutral on Cisco Systems, Raises Price Target to $64

EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) has outperformed the market over the past 10 years by 15.26% on an annualized basis producing an average annual return of 25.98%. Currently, EMCOR Group has a market capitalization of $21.04 billion. 
Buying $1000 In EME: If an investor had bought $1000 of EME stock 10 years ago, it would be worth $10,162.32 today based on a price of $467.00 for EME at the time of writing.
<h3>EMCOR Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747325713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Piper Sandler analyst David Amsellem maintains Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) with a Overweight and lowers the price target from $24 to $18.

Piper Sandler Maintains Overweight on Organon, Lowers Price Target to $18

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) with a Overweight and raises the price target from $2.5 to $5.

CTMX

Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $5

<ul>
<li>Mark King Intends to Retire</li>
<li>Will Continue to Serve Until a Successor is Appointed</li>
<li>Board of Directors Is Conducting a Succession Planning Process</li>
</ul>
Xponential Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) ("Xponential" or the "Company"), one of the leading global franchisors of boutique health and wellness brands, announced today that Mark King, Chief Executive Officer, has informed the Board of Directors that he intends to retire as the Company's CEO and as a Director due to health reasons. To ensure a smooth transition, Mr. King will continue to serve as CEO throughout the search process for a successor until his retirement.

Management

XPOF

Reported Earlier: Xponential Fitness CEO Mark King To Retire Due To Health Reasons, Will Remain In Role Until Successor Is Appointed As Board Conducts Succession Search

JP Morgan analyst Matthew Boss upgrades Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) from Underweight to Neutral and raises the price target from $16 to $24.

Upgrades

JP Morgan Upgrades Foot Locker to Neutral, Raises Price Target to $24

WIIM

SATL

Satellogic shares are trading higher. On Tuesday, the company reported a year-over-year increase in Q1 sales results.

IMMP

Immutep shares are trading higher after the company announced response rate data of  Efti with KEYTRUDA & chemotherapy.

Piper Sandler analyst David Westenberg maintains Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) with a Neutral and raises the price target from $55 to $70.

Piper Sandler Maintains Neutral on Tempus AI, Raises Price Target to $70

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2 to $1.25.

PACB

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $205 to $210.

NTRA

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $210

Jefferies analyst Julien Dumoulin-Smith downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Hold to Underperform and lowers the price target from $4 to $3.

Downgrades

FLNC

Jefferies Downgrades Fluence Energy to Underperform, Lowers Price Target to $3

Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Overweight and lowers the price target from $12.5 to $9.

MYGN

Piper Sandler Maintains Overweight on Myriad Genetics, Lowers Price Target to $9

AEVA

Aeva Technologies shares are trading higher after the company reported better-than-expected Q1 financial results.

DA Davidson analyst Brent Thielman maintains Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) with a Neutral and raises the price target from $58 to $68.

DA Davidson Maintains Neutral on Everus Construction Group, Raises Price Target to $68

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and lowers the price target from $190 to $185.

ILMN

Piper Sandler Maintains Overweight on Illumina, Lowers Price Target to $185

<a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf" title="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf">https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf</a>

MIRA

Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

After rising in tandem last year as hedges against currency depreciation, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold are <a href="https://www.benzinga.com/25/05/45410910/bitcoin-considered-digital-gold-while-it-reaches-103k">no longer moving in sync.</a>
What Happened: According to JPMorgan, the two assets have entered a zero-sum phase in 2025, with gains in one increasingly coming at the other's expense, The Block <a href="https://www.theblock.co/post/354496/jpmorgan-bitcoin-more-upside-gold-h2-2025?utm_source=twitter&amp;utm_medium=social">reported</a>.
JPMorgan analysts, led by managing director Nikolaos Panigirtzoglou, noted a reversal in capital flows in recent months. 
From mid-February to mid-April, gold outperformed while Bitcoin lagged. 
But since late April, the trend has flipped: Bitcoin has climbed 18% while gold has dropped nearly 8%. 
Investor flows and futures data support this divergence, with capital leaving gold ETFs and entering Bitcoin funds.
The bank's strategists expect this competitive dynamic between the two assets to persist through the remainder of the year, though they see more potential upside for Bitcoin. 
&#8220;We are biased towards crypto-specific catalysts creating more upside for Bitcoin over gold into the second half of the year,&#8221; the note said.
One major factor behind Bitcoin's rise is increased institutional and public sector adoption. 
Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Metaplanet have continued accumulating Bitcoin aggressively.
Strategy alone has already secured 60% of its $42 billion goal for Bitcoin purchases, targeting completion by 2027.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a>
Why It Matters: U.S. states are also starting to allocate to Bitcoin.
New Hampshire now permits up to 5% of state assets in Bitcoin and gold, and Arizona is establishing a digital asset reserve fueled by staking yields and token airdrops, while pledging to hold taxes steady.
These developments signal growing acceptance of Bitcoin as a strategic reserve asset. 
JPMorgan believes this trend may become more significant if more states follow suit.
At the same time, structural changes in the crypto derivatives market are boosting investor confidence. 
Coinbase's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) acquisition of Deribit, Kraken's purchase of NinjaTrader, and Gemini's expansion into European derivatives licensing are seen as milestones that could usher in greater institutional engagement, particularly as regulatory clarity improves.
Altogether, with gold under pressure and Bitcoin buoyed by sector-specific growth, JPMorgan sees the second half of the year tilting in favor of the leading cryptocurrency.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45438872/want-to-copytrade-the-trump-linked-world-liberty-financial-portfolio-dont-be-so-sure">Want To Copytrade The Trump-Linked World Liberty Financial Portfolio? Don&#8217;t Be So Sure</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

MSTR

Bitcoin Is Starting To Outperform Gold: JPMorgan

Biotech

General

VTVT

vTv Therapeutics Resumes Screening In Phase 3 CATT1 Study Evaluating Cadisegliatin as Adjunctive Therapy for Type 1 Diabetes

Piper Sandler analyst Mark Lear maintains Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) with a Neutral and lowers the price target from $16 to $15.

VTLE

Piper Sandler Maintains Neutral on Vital Energy, Lowers Price Target to $15

Press Releases

Gabelli Funds to Host 48th Annual Automotive Symposium at The Encore at Wynn, Las Vegas, Nevada

Garrett Motion Announces Long-Term Capital Allocation Framework, Including New Quarterly Dividend and $250M Share Repurchase Program for 2025

Financing

Garrett Motion Announces Term Loan and Revolving Credit Facility Refinancing and Extension

Garrett Motion to Hold Fourth Quarter 2024 Financial Results Conference Call on Thursday February 20, 2025

QXO Proposes Full Slate of Independent Directors for Election at Beacon Roofing Supply's 2025 Annual Meeting

Earnings

Garrett Motion Delivers Strong 2024 Financial Performance, Issues 2025 Outlook

Garrett Motion to Hold First Quarter 2025 Financial Results Conference Call on Thursday May 01, 2025

Advancing Motion: Garrett Presents Breakthrough Electrification and Turbocharging Innovations at Auto Shanghai 2025

Garrett and HanDe Sign Strategic Partnership, Including Series Production Award to Accelerate Electrification of Heavy-Duty Trucks with Advanced E-Axle Systems

Garrett Motion Reports First Quarter 2025 Financial Results; Wins First Major Series Production Award For Electric Motors

AMWD

AVNT

BECN

BERY

DORM

FERG

FLXS

GNTX

MNRO

MPAA

NNBR

ORLY

PGTI

PHIN

PRTS

RDUS

RUSHA

SIEGY

STLD

STRT

UNVR

XONE

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Garrett Motion

ニュース

最新ニュース Garrett Motion (NASDAQ:GTX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル